Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Authors
Keywords
-
Journal
Lancet Diabetes & Endocrinology
Volume 10, Issue 6, Pages 393-406
Publisher
Elsevier BV
Online
2022-04-23
DOI
10.1016/s2213-8587(22)00070-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Why does obesity cause diabetes?
- (2022) Samuel Klein et al. Cell Metabolism
- Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
- (2021) Alessandro Mantovani et al. Metabolites
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial
- (2021) Ian J Neeland et al. Lancet Diabetes & Endocrinology
- Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
- (2021) Anne Flint et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Cardiometabolic Health Outcomes Associated With Discordant Visceral and Liver Fat Phenotypes: Insights From the Dallas Heart Study and UK Biobank
- (2021) Sanaa Tejani et al. MAYO CLINIC PROCEEDINGS
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
- (2020) Mark L. Hartman et al. DIABETES CARE
- Nonalcoholic Steatohepatitis
- (2020) Adam C. Sheka et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- How May GIP Enhance the Therapeutic Efficacy of GLP-1?
- (2020) Ricardo J. Samms et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Causes, consequences, and treatment of metabolically unhealthy fat distribution
- (2020) Norbert Stefan Lancet Diabetes & Endocrinology
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis
- (2019) Zobair M. Younossi et al. JOURNAL OF HEPATOLOGY
- Crosstalk between adipose tissue insulin resistance and liver macrophages in Non Alcoholic Fatty Liver Disease
- (2019) Chiara Rosso et al. JOURNAL OF HEPATOLOGY
- Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis
- (2019) Fernando Bril et al. JOURNAL OF HEPATOLOGY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- Incretin hormones: Their role in health and disease
- (2018) Michael A. Nauck et al. DIABETES OBESITY & METABOLISM
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease
- (2017) Fernando Bril et al. HEPATOLOGY
- Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes
- (2016) K. Cusi et al. DIABETES OBESITY & METABOLISM
- Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
- (2016) A. Dutour et al. DIABETES OBESITY & METABOLISM
- Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study
- (2016) Amalia Gastaldelli et al. HEPATOLOGY
- Insulin Plays a Permissive Role for the Vasoactive Effect of GIP Regulating Adipose Tissue Metabolism in Humans
- (2016) Meena Asmar et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
- (2016) Matthew J. Armstrong et al. JOURNAL OF HEPATOLOGY
- The blunted effect of glucose-dependent insulinotropic polypeptide in subcutaneous abdominal adipose tissue in obese subjects is partly reversed by weight loss
- (2016) M Asmar et al. Nutrition & Diabetes
- Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis
- (2016) Janki Patel et al. Therapeutic Advances in Gastroenterology
- Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
- (2015) An Tang et al. DIABETES CARE
- Accuracy of MR Imaging–estimated Proton Density Fat Fraction for Classification of Dichotomized Histologic Steatosis Grades in Nonalcoholic Fatty Liver Disease
- (2015) An Tang et al. RADIOLOGY
- Extrahepatic complications of nonalcoholic fatty liver disease
- (2013) Matthew J. Armstrong et al. HEPATOLOGY
- Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
- (2012) Daniel J. Cuthbertson et al. PLoS One
- Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease
- (2011) Romina Lomonaco et al. HEPATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More